RxDoctor Payments Data

Bradley Clark, MD

Nuclear Cardiology · Clemmons, NCNPI 1639431307

Payments from drug & device makers

$151,573in general payments, 2019–2025

Across 433 payments — averaging $350.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$91K
  • Johnson & Johnson$33K
  • Sanofi-aventis U.S. LLC$12K
  • Lilly USA, LLC$11K
  • Medtronic$945
  • Novartis$800
  • plus $3K from 13 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$141,34893%
  • Travel & lodging$2,2822%
  • Food & beverage$7,6425%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nuclear cardiology providers in North Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$124,143
Medicare patients
1,116
Services billed
2,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban644$608,056
EntrestoSacubitril/Valsartan258$287,365
JardianceEmpagliflozin234$219,085
XareltoRivaroxaban227$216,890
Repatha SureclickEvolocumab257$179,358
CamzyosMavacamten13$109,993
Droxidopa21$37,335
Praluent PenAlirocumab32$19,431
FarxigaDapagliflozin Propanediol26$18,281
CorlanorIvabradine Hcl18$16,282
Repatha SyringeEvolocumab17$15,368
Metoprolol Succinate867$10,207
Ranolazine ErRanolazine65$5,874
Rosuvastatin Calcium527$4,326
Ezetimibe270$3,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$162$608,056644 claims
NovartisEntresto$800$287,365258 claims
Boehringer IngelheimJardiance$90,870$219,085234 claims
Johnson & JohnsonXarelto$32,969$216,890227 claims
E.r. Squibb & Sons, L.L.C.Camzyos$377$109,99313 claims
AstraZenecaFarxiga$499$18,28126 claims
AmgenCorlanor$361$16,28218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nuclear cardiology providers in North Carolinaon file to place this against a meaningful peer group, so we don't.

Other nuclear cardiology in Clemmons

Where these figures come from

Is this you, or does something look wrong? →